- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04462523
DEXTENZA for the Treatment of Postoperative Pain and Inflammation Following Vitreo-retinal Surgery
June 14, 2023 updated by: Patrick R. Oellers, MD
Open-label, Single -Center, Prospective Study on the Efficacy and Safety of Intracanalicular Dexamethasone Insert 0.4mg (Dextenza) in the Treatment of Postoperative Pain and Inflammation Following Vitreo-retinal Surgery - The ADHERE Study
The purpose of this study is to evaluate efficacy and safety of Dextenza for the treatment of postoperative pain and inflammation following vitreo-retinal surgery
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This prospective, single-center, open-label, investigator-sponsored clinical study seeks to investigate the outcomes of patients undergoing vitro-retinal surgery with the treatment of a dexamethasone intracanalicular insert.
All patients in the treatment groups will receive a dexamethasone intracanalicular insert.
There will be three experimental groups of patients, varying that time of insertion.
Ten patients will receive the dexamethasone intracanalicular insert pre-operatively (1 week to 1 days prior to vitreo-retinal surgery).
Ten patients will receive dexamethasone intracanalicular insert on the day of surgery.
Ten patients will receive DEXTENZA insert Day 1 post-operatively.
Ten patients will be prescribed standard of care ophthalmic drops, Prednisolone Acetate, and no dexamethasone insert (control group).
All patients no matter what cohort will receive Gentamicin, antibiotic ophthalmic drops.
Study Type
Interventional
Enrollment (Actual)
40
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Christine Dorr
- Phone Number: 5655 315-445-8166
- Email: cdorr@rvscny.com
Study Locations
-
-
New York
-
Liverpool, New York, United States, 13088
- Retina Vitreous Surgeons of Central New York, PC
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Any adult patient age 18-99 years who is planned to undergo vitreo-retinal surgery (pars plana vitrectomy with or without scleral buckle).
- If both eyes are involved, both eyes would be eligible for the study.
- Willing and able to comply with clinic visits and study related procedures.
- Willing and able to sign the informed consent form.
Exclusion Criteria:
- Patients under age 18.
- Patients who are pregnant (must be ruled out in women of child-bearing age with pregnancy test).
- Active infectious ocular or systemic disease.
- Patients with active infectious ocular or extraocular disease.
- Patients actively treated with local or systemic immunosuppression
- Use of the following anti-inflammatory or immunomodulating agents (e.g., cyclosporine) systemically, or in the study eye, for the duration of the study (excluding inhalants). Washout periods for medications prior to surgery are as follows:
- Systemic corticosteroids - 2 weeks (see exception 5c)
- Systemic NSAID over 375 mg per day - 2 weeks
- Periocular/intraocular injection of any corticosteroid solution - 4 weeks (see exception 5b)
- Corticosteroid depot/implant in the study eye - 2 months
- Topical ocular corticosteroid - 7 days
- Topical ocular NSAID - 7 days
- Intraoperatively used intraocular steroid (i.e. intravitreal triamcinolone, that is used to transiently highlight the vitreous and removed during vitrectomy) is permissible in study eye.
- Intraoperatively or perioperatively used systemic steroid for the purpose of general anesthesia (as administered by the treating anesthesiologist) is permissible.
- Patients with systemic illness involving abnormalities of the hypothalamic-pituitary-adrenal axis; patients with primary adrenocortical insufficiency or adrenocortical hyperfunction.
- Patients with known hypersensitivity to Dexamethasone.
- Patients with uncontrolled glaucoma.
- Patients with severe disease that warrants critical attention, deemed unsafe for the study by the investigator.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Group 1 Pre-surgery Dextenza insert
Ten patients will receive the dexamethasone intracanalicular insert pre-operatively (1 week to 1 days prior to vitreo-retinal surgery).
All patients no matter what cohort will receive Gentamicin, antibiotic ophthalmic drops.
|
The insert, containing 0.4 mg of active pharmaceutical product, is placed within the canaliculus to provide a sustained and tapered delivery of drug to the ocular surface over 30 days after a one-time insertion.
The attributes of the insert reduce the risks for improper corticosteroid tapering and unwanted peaks and troughs in drug concentration.
|
Experimental: Group 2 Surgery Day Dextenza insert
Ten patients will receive dexamethasone intracanalicular insert on the day of surgery.
All patients no matter what cohort will receive Gentamicin, antibiotic ophthalmic drops.
|
The insert, containing 0.4 mg of active pharmaceutical product, is placed within the canaliculus to provide a sustained and tapered delivery of drug to the ocular surface over 30 days after a one-time insertion.
The attributes of the insert reduce the risks for improper corticosteroid tapering and unwanted peaks and troughs in drug concentration.
|
Experimental: Group 3 Post op Day 1 Dextenza insert
Ten patients will receive DEXTENZA insert Day 1 post-operatively.
All patients no matter what cohort will receive Gentamicin, antibiotic ophthalmic drops
|
The insert, containing 0.4 mg of active pharmaceutical product, is placed within the canaliculus to provide a sustained and tapered delivery of drug to the ocular surface over 30 days after a one-time insertion.
The attributes of the insert reduce the risks for improper corticosteroid tapering and unwanted peaks and troughs in drug concentration.
|
Active Comparator: Group 4 Topical steroid
Ten patients will be prescribed standard of care ophthalmic drops, Prednisolone Acetate, and no dexamethasone insert (control group).
All patients no matter what cohort will receive Gentamicin, antibiotic ophthalmic drops.
|
Standard of care topical drop treatment
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean cells as assessed by investigator in anterior chamber of the study eye
Time Frame: Assessed at Day 14
|
As measure by Standardization of Uveitis Nomenclature (SUN Scale) (Grade 0 to Grade 4+)
|
Assessed at Day 14
|
Mean pain as reported by subject in the study eye: Visual Analog Scale
Time Frame: Assessed at Day 28
|
As measured by Visual Analog Scale for Pain (VAS Pain) (0% to 100% Scale)
|
Assessed at Day 28
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean anterior chamber flare
Time Frame: Assessed at Screening, Day 1, Day 4, Day 14, Day 28 and Day 56
|
As measure by Standardization of Uveitis Nomenclature (SUN Scale) (Grade 0 to Grade 4+)
|
Assessed at Screening, Day 1, Day 4, Day 14, Day 28 and Day 56
|
Time to absence of cells
Time Frame: Assessed at Screening, Day 1, Day 4, Day 14, Day 28 and Day 56
|
As measure by Standardization of Uveitis Nomenclature (SUN Scale) (Grade 0 to Grade 4+)
|
Assessed at Screening, Day 1, Day 4, Day 14, Day 28 and Day 56
|
Time to absence of pain
Time Frame: Assessed at Screening, Day 1, Day 4, Day 14, Day 28 and Day 56
|
As measure by Visual Analog Scale for Pain (VAS Pain) (0% to 100% Scale)
|
Assessed at Screening, Day 1, Day 4, Day 14, Day 28 and Day 56
|
Proportion of rescue treatment
Time Frame: Assessed at Screening, Day 1, Day 4, Day 14, Day 28 and Day 56
|
As measure by Concomitant Medications as rescue therapy
|
Assessed at Screening, Day 1, Day 4, Day 14, Day 28 and Day 56
|
Assessment of Dextenza ease of insertion
Time Frame: Assessed at Day 1
|
As measured by Ease of Use Survey (0=very easy to 10=very hard)
|
Assessed at Day 1
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 3, 2020
Primary Completion (Actual)
March 31, 2022
Study Completion (Actual)
March 31, 2022
Study Registration Dates
First Submitted
June 24, 2020
First Submitted That Met QC Criteria
July 7, 2020
First Posted (Actual)
July 8, 2020
Study Record Updates
Last Update Posted (Actual)
June 15, 2023
Last Update Submitted That Met QC Criteria
June 14, 2023
Last Verified
June 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Postoperative Complications
- Pain
- Neurologic Manifestations
- Pain, Postoperative
- Inflammation
- Physiological Effects of Drugs
- Anti-Inflammatory Agents
- Antineoplastic Agents
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Prednisolone
Other Study ID Numbers
- The ADHERE Study
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Vitreo-Retinal Surgery
-
BioFirst CorporationCompleted
-
University of California, San FranciscoCompletedDevelopment of Ptosis After Vitreo-retinal SurgeryUnited States
-
The S.N. Fyodorov Eye Microsurgery State InstitutionCompletedVitreoretinal Detachment | Vitreo-Retinal AdhesionRussian Federation
-
Mansoura UniversityCompletedRetinal Surgery
-
Xinhua Hospital, Shanghai Jiao Tong University...CompletedSurgery | Macular HoleChina
-
Kyorin UniversityCompletedMacular Hole Surgery
-
Peking University People's HospitalPeking Union Medical College Hospital; Beijing Tongren Hospital; Beijing HospitalUnknown
-
Kyorin UniversityCompletedSurgery | High Myopia | MaculopathyJapan
-
San Ni ChenCompletedSurgery | Retinal Detachment
-
Fondation Ophtalmologique Adolphe de RothschildCompletedMacular Hole SurgeryFrance
Clinical Trials on Dextenza 0.4Mg Ophthalmic Insert
-
Cathleen McCabe MDOcular Therapeutix, Inc.Terminated
-
Nicole Fram M.D.CompletedCataract Senile | Anterior Chamber Inflammation | Ocular Pain | Corneal Edema | Corneal Defect | Penetrating KeratoPlasty | Nuclear Cataract | Cortical CataractUnited States
-
Navy Medical Center San DiegoNot yet recruitingSteroid Ophthalmic Insert
-
Eye Associates of Central TexasWithdrawn
-
Mitchel IbachOcular Therapeutix, Inc.Not yet recruiting
-
Vance Thompson VisionOcular Therapeutix, Inc.CompletedRefractive SurgeryUnited States
-
Vance Thompson VisionUnknownRefractive SurgeryUnited States
-
Nathan SteinleOcular Therapeutix, Inc.UnknownOcular Disease Requiring SurgeryUnited States
-
Eye Surgeons of IndianaOcular Therapeutix, Inc.Terminated
-
Nicole Fram M.D.RecruitingAnterior Chamber Inflammation | Ocular Pain | Corneal Edema | Corneal Defect | Corneal Staining | Visual Outcome | CME - Cystoid Macular EdemaUnited States